---
title: "Bluejay Diagnostics surges 36% as premarket momentum carries into session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294988511.md"
description: "Bluejay Diagnostics (BJDX) climbed 36% to $1.36 in Wednesday trading, extending a 40% premarket rally."
datetime: "2026-08-05T15:31:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294988511.md)
  - [en](https://longbridge.com/en/news/294988511.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294988511.md)
generator: "portal-rs"
---

# Bluejay Diagnostics surges 36% as premarket momentum carries into session

Bluejay Diagnostics(BJDX.US) 盘中时段 5 分钟内急涨超 3%，现报**1.36 美元**，当日累计涨超**36%**。此前该股在盘前交易中已上涨约 40%，盘中继续维持买盘动能，成交量达 5641.27 万股。

消息面上，医疗保健板块周二盘后及周三盘前出现多只异动个股，Bluejay Diagnostics 位列盘前涨幅榜前列。消息面暂无该公司当日新增催化剂。

### Related Stocks

- [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md)

## Related News & Research

- [Bluejay Diagnostics says SYMON-II pivotal study completes enrollment of 750 patients for Symphony IL-6 test](https://longbridge.com/en/news/295778817.md)
- [Bluejay responds to investor on possible therapeutic acquisition while prioritizing Symphony platform execution](https://longbridge.com/en/news/279242759.md)
- [Bluejay 10-K: Net loss $6.85M, operating loss $6.95M; cash through Q3 2026](https://longbridge.com/en/news/278166044.md)
- [Bluejay Diagnostics announces SYMON-II sepsis study enrollment completion](https://longbridge.com/en/news/293326776.md)
- [Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study](https://longbridge.com/en/news/293531257.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**